

09/982,315

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/CAPLUS patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAPLUS enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 13 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c; CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

McIntosh

09/982,315

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAR 2007 HIGHEST RN 926905-73-9
DICTIONARY FILE UPDATES: 16 MAR 2007 HIGHEST RN 926905-73-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>


=>
Uploading C:\Program Files\Stnexp\Queries\09982315b.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, OH, MeO

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 17:40:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 786183 TO ITERATE

100.0% PROCESSED 786183 ITERATIONS
SEARCH TIME: 00.00.04

2160 ANSWERS

L2 2160 SEA SSS FUL L1

→ compound a

=> e resveratrol/cn

E1	1	RESUSCITATION-PROMOTING FACTOR RPFE (MYCOBACTERIUM ULCERANS STRAIN AGY99 GENE RPFE)/CN
E2	1	RESUSCITATION-PROMOTING FACTOR-LIKE PROTEIN (MYCOBACTERIUM ULCERANS STRAIN AGY99)/CN
E3	1 -->	RESVERATROL/CN
E4	1	RESVERATROL B-D-GLUCOSIDE/CN
E5	1	RESVERATROL 12-C-B-GLUCOPYRANOSIDE/CN
E6	1	RESVERATROL 3-O-B-GLUCOPYRANOSIDE/CN
E7	1	RESVERATROL 3-O-GLUCURONIDE/CN
E8	1	RESVERATROL 4'-O-B-D-GLUCOPYRANOSIDE/CN
E9	1	RESVERATROL 4'-O-GLUCURONIDE/CN
E10	1	RESVERATROL CIS-DEHYDRODIMER/CN

McIntosh

09/982,315

E11 1 RESVERATROL GLUCOSIDE/CN
E12 1 RESVERATROL SYNTHASE/CN

=> s e3

L3 1 RESVERATROL/CN

=> e ascorbic acid/cn

E1 1 ASCORBATE-TRANSPORTING PROTEIN SVCT2 (RATTUS RATTUS)/CN
E2 1 ASCORBATE: TMPD OXIDASE/CN
E3 2 --> ASCORBIC ACID/CN
E4 1 ASCORBIC ACID 2,5,6-TRISULFATE POTASSIUM SALT/CN
E5 1 ASCORBIC ACID 2,5,6-TRISULFATE SODIUM SALT/CN
E6 1 ASCORBIC ACID 2-PHOSPHATE/CN
E7 1 ASCORBIC ACID 2-PHOSPHATE MAGNESIUM SALT/CN
E8 1 ASCORBIC ACID 2-PYROPHOSPHATE/CN
E9 1 ASCORBIC ACID 2-PYROPHOSPHATE SODIUM SALT/CN
E10 1 ASCORBIC ACID 2-SULFATE/CN
E11 1 ASCORBIC ACID 2-SULFATE DEHYDROGENASE/CN
E12 1 ASCORBIC ACID 2-SULFATE DIPOTASSIUM SALT/CN

=> s e3

L4 2 "ASCORBIC ACID"/CN

=> e dehydroascorbic acid/cn

E1 1 DEHYDROASCORBATE REDUCTASE (SPINACH CHLOROPLAST-ASSOCIATED P
RECURSOR)/CN
E2 1 DEHYDROASCORBATE REDUCTASE, GSH-DEPENDENT (ORYZA SATIVA)/CN
E3 2 --> DEHYDROASCORBIC ACID/CN
E4 2 DEHYDROASCORBIC ACID REDUCTASE/CN
E5 1 DEHYDROASCORBIC ACID, 2,3':2',3-DIANHYDRIDE, TETRAACETATE, L
-/CN
E6 1 DEHYDROASCORBIC ACID, 2,3-BIS((2,4-DINITROPHENYL)HYDRAZONE),
L-/CN
E7 1 DEHYDROASCORBIC ACID, 2,3-BIS(4-(P-BROMOPHENYL)-3-THIOSEMICAR
BAZONE)/CN
E8 1 DEHYDROASCORBIC ACID, 2,3-BIS(PHENYLHYDRAZONE), 5,6-DI-P-TOL
UENESULFONATE, L-/CN
E9 1 DEHYDROASCORBIC ACID, 2,3-BIS(PHENYLHYDRAZONE), 6-P-TOLUENES
ULFONATE, L-/CN
E10 1 DEHYDROASCORBIC ACID, 2,3-BIS(PHENYLHYDRAZONE), L-/CN
E11 1 DEHYDROASCORBIC ACID, 2-(PHENYLHYDRAZONE), L-/CN
E12 1 DEHYDROASCORBIC ACID, BIS((2,4-DINITROPHENYL)HYDRAZONE)/CN

=> s e3

L5 2 "DEHYDROASCORBIC ACID"/CN

=> e ascorbate/cn

E1 1 ASCORBALAMIC ACID/CN
E2 1 ASCORBATE/CN
E3 1 --> ASCORBATE/CN
E4 1 ASCORBATE 2,3-DIOXYGENASE/CN
E5 1 ASCORBATE 2-KINASE/CN
E6 1 ASCORBATE 2-PHOSPHATASE/CN
E7 1 ASCORBATE 2-SULFATASE/CN
E8 1 ASCORBATE 2-SULFATE SULFOHYDROLASE/CN
E9 1 ASCORBATE ANION/CN
E10 1 ASCORBATE DEHYDROGENASE/CN
E11 1 ASCORBATE DIANION/CN
E12 1 ASCORBATE FREE RADICAL PEROXIDASE/CN

=> s e3

L6 1 ASCORBATE/CN

=> e ascorbate salt/cn

E1 2 ASCORBATE PEROXIDASE (TOBACCO CHLOROPLAST-ASSOCIATED)/CN
E2 2 ASCORBATE RADICAL/CN
E3 0 --> ASCORBATE SALT/CN
E4 1 ASCORBATE(1-)/CN
E5 1 ASCORBATE(2-)/CN
E6 1 ASCORBATE-CYTOCHROME B5 REDUCTASE/CN
E7 1 ASCORBATE-CYTOCHROME B558 REDUCTASE/CN
E8 1 ASCORBATE-DEPENDENT MONOOXYGENASE (FRANKIA ALNI STRAIN ACN14
A)/CN
E9 1 ASCORBATE-DEPENDENT PEROXIDASE (LEISHMANIA MAJOR STRAIN FRIE
DLIN)/CN

McIntosh

09/982,315

E10 1 ASCORBATE-GLUTATHIONE DEHYDROGENASE/CN
E11 1 ASCORBATE-N,N,N',N'-TETRAMETHYL-P-PHENYLENEDIAMINE DIHYDROCH
LORIDE/CN
E12 1 ASCORBATE-SPECIFIC PEROXIDASE/CN

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1 STRUCTURE UPLOADED
L2 2160 S L1 FULL
E RESVERATROL/CN
L3 1 S E3
E ASCORBIC ACID/CN
L4 2 S E3
E DEHYDROASCORBIC ACID/CN
L5 2 S E3
E ASCORBATE/CN
L6 1 S E3
E ASCORBATE SALT/CN

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

193.25

193.46

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Mar 2007 VOL 146 ISS 13

FILE LAST UPDATED: 16 Mar 2007 (20070316/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12 and (13 or 14 or 15 or 16)

8642 L2

2961 L3

83031 L4

3153 L5

297 L6

L7 362 L2 AND (L3 OR L4 OR L5 OR L6)

=> s 17 and pulmonary

88948 PULMONARY

2 PULMONARIES

88948 PULMONARY

(PULMONARY OR PULMONARIES)

L8 9 L7 AND PULMONARY

=> d bib abs hitstr 1-9 18

L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:61185 CAPLUS

DN 146:169320

TI Compositions for treating or preventing obesity, insulin resistance and mitochondrial-associated disorders

IN Milburn, Michael; Milne, Jill; Auwerx, Johan; Argmann, Carmen; Lagouge, Marie; Dipp, Michelle

McIntosh


→ combo a + b

09/982,315

PA Sirtris Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 337pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008548	A2	20070118	WO 2006-US26272	20060707
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-697443P	P	20050707		
	US 2005-736528P	P	20051114		
	US 2005-753606P	P	20051223		
	US 2006-783802P	P	20060316		
AB	Provided herein are methods and comps. for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide. Resveratrol increases the PGC-1 protein deacetylation.				
IT	480-41-1, Naringenin 501-36-0 215257-15-1 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (comps. for treating or preventing obesity and insulin resistance and mitochondrial-associated disorders)				
RN	480-41-1 CAPLUS				
CN	4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)				

Absolute stereochemistry.




RN 501-36-0 CAPLUS
CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 215257-15-1 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)


McIntosh



L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:34293 CAPLUS
 DN 146:135598
 TI Nrf2-based compositions and methods for the treatment or prevention of disorders relating to oxidative stress
 IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy, Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh, Anju
 PA The Johns Hopkins University, USA
 SO PCT Int. Appl., 249pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007005879	A2	20070111	WO 2006-US26056	20060703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-696485P	P	20050701		
US 2006-800975P	P	20060517		
AB	The invention discloses methods for treating or preventing conditions, diseases, or disorders related to oxidative stress. In one embodiment, the method increases Nrf2 biol. activity or expression. In particular, the invention provides for the treatment or prevention of diseases relating to oxidative stress including emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia and neurodegenerative disorders, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia, cognitive deficits and neurodegenerative disorders.			
IT	501-36-0, Resveratrol 552-58-9, Eriodictyol RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Nrf2-based compns. and methods for treatment or prevention of oxidative stress-related disorders)			
RN	501-36-0 CAPLUS			
CN	1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)			

Double bond geometry as shown.




09/982,315

RN 552-58-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-,
(2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1279474 CAPLUS

DN 146:39038

TI Compositions comprising nebivolol for the treatment of cardiovascular diseases

IN Davis, Eric; O'Donnell, John; Bottini, Peter Bruce; Mason, Preston; Shaw, Andrew Preston

PA Mylan Laboratories, Inc., USA

SO PCT Int. Appl., 112pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006130174	A2	20061207	WO 2005-US41275	20051116
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2005272810	A1	20051208	US 2005-141235	20050531
PRAI	US 2005-141235	A	20050531		
	US 2005-272562	A	20051110		
	US 2005-273992	A	20051115		
	US 2004-577423P	P	20040604		

AB Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent. There were significant concentration dependent effects on the ability of nebivolol to enhance NO release from human endothelial cells that had been chronically treated with ACE inhibitors. Addnl., this property of the drug appears to work independently of β 1-adrenoceptor blockade.

IT 480-18-2, Taxifolin 501-36-0, Resveratrol


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compsn. comprising nebivolol for treatment of cardiovascular diseases)

RN 480-18-2 CAPLUS


CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 501-36-0 CAPLUS
 CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:796329 CAPLUS
 DN 145:224864
 TI Hydroxylated nebivolol metabolites for treating and/or preventing vascular diseases
 IN O'Donnell, John P.; Owens, Walter; Duncan, Joseph; Shaw, Andrew; Wu, Jinn
 PA Mylan Laboratories, Inc., USA
 SO PCT Int. Appl., 120pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006083779	A2	20060810	WO 2006-US3252	20060130
	WO 2006083779	A3	20061123		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2007014733	A1	20070118	US 2006-342497	20060130
PRAI	US 2005-648551P	P	20050131		
	US 2006-755856P	P	20060103		

AB Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preps. in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6'-difluoro-, 4-hydroxy-5-phenol-6,6'-difluoro-, and 4-hydroxy-8-phenol-6,6'-difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compns. comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one addnl. compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one

hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders. Thus, acute treatment with six stereoselective hydroxy metabolites in endothelial cells from both white and black American donors showed that all six hydroxy metabolites have activity that was much superior to d-nebivolol, and most are superior to nebivolol racemate. As compared to nebivolol, the 4'-(R)-hydroxy-7-fluoro-6-hydroxy-1-nebivolol metabolite caused a nearly two-fold increase in NO release to 476 ± 20 and 383 ± 18 nmol/L, resp., from white and black donors. The 4'-(R)-hydroxy-5-fluoro-1-nebivolol metabolite also exceeded the activity of nebivolol and even 1-nebivolol by >50%. These findings indicate that hydroxy metabolites of nebivolol have distinct and highly reproducible effects on acute NO release in human endothelial cells.


IT 480-18-2, Taxifolin 501-36-0, Resveratrol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxylated nebivolol metabolites for increase of NO release from endothelium in combination with other agent(s) for treating and/or preventing vascular diseases)

RN 480-18-2 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:211502 CAPLUS

DN 144:267270

TI Fused bicyclic natural compounds and their use as inhibitors of PARP and PARP-mediated inflammatory processes

IN Hageman, Gerrigje Johanna; Moonen, Harald Johan Joseph; Geraets, Liesbeth; Bast, Aalt; Wouters, Emiel Frans Maria

PA Stichting voor de Technische Wetenschappen, Neth.

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

09/982,315


PI WO 2006024545 A1 20060309 WO 2005-EP9514 20050905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
PRAI EP 2004-447196 A 20040903
EP 2004-447238 A 20041028
OS MARPAT 144:267270

AB The invention relates to the use of at least two compds., of which the first compound is a natural compound such as xanthines, coumarins, flavonoids, and anthocyanidins which are identified as PARP-1 (poly(ADP-ribose) polymerase 1) inhibitors and a second compound, which is an NAD⁺ precursor for preparing medicaments, medical foods or nutraceuticals. The invention also relates to the use of these compds. or pharmaceutical compns. comprising at least two of these compds. as anti-inflammatory agent for treating acute or chronic inflammation in certain diseases or disorders.

IT 480-18-2, Taxifolin 480-18-2D, Taxifolin, derivs. and esters metabolites and prodrugs 480-41-1, Naringenin 480-41-1D, Naringenin, derivs. and esters metabolites and prodrugs 501-36-0, Resveratrol
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fused bicyclic natural compds. and their use as inhibitors of PARP and PARP-mediated inflammatory processes and combination with NAD⁺ precursors)


RN 480-18-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 480-18-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 480-41-1 CAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-,

McIntosh

09/982,315

(2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 480-41-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-,
(2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:964594 CAPLUS

DN 141:406143

TI Method and composition for preventing or reducing edema, deep vein
thrombosis and/or pulmonary embolism

IN Riordan, Neil H.

PA USA

SO U.S. Pat. Appl. Publ., 18 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004223962	A1	20041111	US 2003-647131	20030822
	WO 2004100879	A2	20041125	WO 2004-US14010	20040505
	WO 2004100879	A3	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

McIntosh

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

EP 1631303 A2 20060308 EP 2004-751406 20040505
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 US 2006222641 A1 20061005 US 2006-452695 20060614
 PRAI US 2003-468948P P 20030507
 US 2003-647131 A 20030822
 WO 2004-US14010 W 20040505


AB The present invention relates to a composition and method for preventing or reducing edema, deep vein thrombosis (DVT), and/or pulmonary embolism by administering a combination of a fibrinolytic agent and an antioxidant. The composition is particularly useful for treating individuals prior to or during long term flights or other situations involving extended immobility.

IT 50-81-7, Vitamin C, biological studies 480-18-2,
 Taxifolin 501-36-0, Resveratrol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism)

RN 50-81-7 CAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 480-18-2 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

09/982,315



L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:824855 CAPLUS
DN 141:320085
TI Compositions and methods for therapy for diseases characterized by defective chloride transport
IN Fischer, Horst; Illek, Beate
PA Children's Hospital Oakland, USA
SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 982,315.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004197272	A1	20041007	US 2004-769619	20040130
	US 5972995	A	19991026	US 1997-951912	19971016
	US 6329422	B1	20011211	US 1998-174077	19981016
	EP 1669067	A2	20060614	EP 2005-17863	19981016
	EP 1669067	A3	20061122		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

	US 2003096762	A1	20030522	US 2001-982315	20011017
PRAI	US 1997-951912	A2	19971016		
	US 1998-174077	A3	19981016		
	US 2001-982315	A2	20011017		
	EP 1998-953609	A3	19981016		

AB Compns. and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compns. comprise one or more compds. such as flavones and/or isoflavones, ascorbate and/or derivs. thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compns. to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport. For example, L-ascorbic acid was found to be able to stimulate the CFTR activity through a cAMP mediated pathway.

IT 50-81-7, L-Ascorbic acid, biological studies 50-81-7D, Ascorbic acid, salts 487-26-3, Flavanone 490-83-5, Dehydroascorbic acid 501-36-0, Resveratrol


RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. containing ascorbates and flavones and isoflavones for therapy for diseases characterized by defective chloride transport)

RN 50-81-7 CAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50-81-7 CAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

09/982,315



RN 487-26-3 CAPLUS


CN 4H-1-Benzopyran-4-one, 2,3-dihydro-2-phenyl- (CA INDEX NAME)



RN 490-83-5 CAPLUS

CN L-threo-2,3-Hexodiulosonic acid, γ -lactone (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:99051 CAPLUS

DN 140:263763

TI Stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids

AU Khanduja, K. L.; Bhardwaj, Anjana

CS Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, 160 012, India

SO Indian Journal of Biochemistry & Biophysics (2003), 40(6), 416-422

CODEN: IJBBBQ; ISSN: 0301-1208

PB National Institute of Science Communication and Information Resources

DT Journal


LA English

AB Stable free radical scavenging and antiperoxidative activities of resveratrol, a component of grapes and red wine, were evaluated and compared with some other known bioflavonoids (quercetin, catechin, kaempferol, myricetin, fisetin, ellagic acid and naringenin) widely present in the plant kingdom. Free radical scavenging activity was measured in an in vitro chemical system (DPPH assay), while for

antiperoxidative activity, biol. system comprising of hepatic and pulmonary homogenates was employed. Antiradical activity assay showed quercetin and myricetin to be stronger antiradical agents than resveratrol. Structure-activity study revealed that O-dihydroxy group on ring B of flavonoid plays a crucial role. A double bond at 2-3 position conjugated with a 4-oxo function and hydroxy groups at positions 3 and 5 also contribute towards antiradical activity of flavonoids. Resveratrol exhibited stronger antiradical activity than kaempferol and naringenin and was also more efficient than α -tocopherol, a known strong endogenous non-flavonoid antioxidant, used for comparison. In vitro antiperoxidative assay showed fisetin as the strongest and kaempferol as the weakest antioxidant. Resveratrol was found to be stronger antioxidant than catechin, myricetin, kaempferol and naringenin, but was weaker than quercetin, fisetin and α -tocopherol. Antiradical and antiperoxidative activities of resveratrol may explain its beneficial effects in disease states. Assays exhibited no direct correlation between antiradical and antiperoxidative activities of the phenolics.


IT 480-41-1, Naringenin 501-36-0, Resveratrol
 RI: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids)
 RN 480-41-1 CAPLUS
 CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 501-36-0 CAPLUS
 CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:10237 CAPLUS
 DN 136:64125
 TI Enhancing therapeutic effectiveness of nitric oxide inhalation
 IN Bloch, Kenneth; Ichinose, Fumito; Zapol, Warren M.
 PA General Hospital Corp., USA
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000175	A2	20020103	WO 2001-US41102	20010622
	WO 2002000175	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2414409 A1 20020103 CA 2001-2414409 20010622
 AU 2001073622 A5 20020108 AU 2001-73622 20010622
 EP 1301076 A2 20030416 EP 2001-952915 20010622

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR


JP 2004509850 T 20040402 JP 2002-504958 20010622
 CN 1635923 A 20050706 CN 2001-811886 20010622
 ZA 2003000702 A 20040709 ZA 2003-702 20030127
 US 2003202969 A1 20031030 US 2003-458578 20030609
 US 6935334 B2 20030830
 PRAI US 2000-605900 A1 20000628
 WO 2001-US41102 W 20010622

AB Methods for reducing, partially preventing or completely preventing nitric oxide (NO) inhalation-related impairment of hypoxic pulmonary vasoconstriction (HPV) in a mammal are disclosed. The methods include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-reactive oxygen species (anti-ROS) agent, e.g., N-acetyl-cysteine, or a leukotriene blocker. Methods for reducing, partially preventing or completely preventing loss of pulmonary vasodilatory responsiveness to NO inhalation in a mammal are also disclosed. The methods include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti ROS agent a therapeutically effective amount of a leukotriene blocker.

IT 50-81-7, Ascorbic acid, biological studies 480-18-2, Taxifolin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (enhancing effectiveness of nitric oxide inhalation as pulmonary vasodilator and preventing impairment of hypoxic pulmonary vasodilator using anti-reactive oxygen species agents and leukotriene blockers)


RN 50-81-7 CAPLUS
 CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 480-18-2 CAPLUS
 CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



09/982,315

=> s 17 and aerosol

61419 AEROSOL

50350 AEROSOLS

76171 AEROSOL

(AEROSOL OR AEROSOLS)

L9 2 L7 AND AEROSOL

=> d bib 1-2 19

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:34293 CAPLUS

DN 146:135598

TI Nrf2-based compositions and methods for the treatment or prevention of disorders relating to oxidative stress

IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy, Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh, Anju

PA The Johns Hopkins University, USA

SO PCT Int. Appl., 249pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005879	A2	20070111	WO 2006-US26056	20060703
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2005-696485P	P	20050701		
US 2006-800975P	P	20060517		

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:376557 CAPLUS

DN 138:367907

TI Nutritional supplements and methods for prevention, reduction and treatment of radiation injury

IN Rosenbloom, Richard A.

PA The Quigley Corporation, USA

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039452	A2	20030515	WO 2002-US13526	20020501
WO 2003039452	A3	20041202		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 2003103953	A1	20030605	US 2001-993003	20011106
US 6753325	B2	20040622		
US 2003103954	A1	20030605	US 2002-45790	20020114
US 2003105027	A1	20030605	US 2002-132642	20020425
CA 2465945	A1	20030515	CA 2002-2465945	20020501
EP 1505984	A2	20050216	EP 2002-736624	20020501
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

09/982,315

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
JP 2005510509	T	20050421 JP 2003-541744 20020501
IN 2004DN01165	A	20060728 IN 2004-DN1165 20040430
PRAI US 2001-993003	A	20011106
US 2002-45790	A	20020114
US 2002-132642	A	20020425
WO 2002-US13526	W	20020501

=> s 17 and (intranasal or inhalation or endopulmonary or nebulizer)

5561 INTRANASAL
36412 INHALATION
713 INHALATIONS
36726 INHALATION
(INHALATION OR INHALATIONS)

0 ENDOPULMONARY

3591 NEBULIZER

677 NEBULIZERS

3797 NEBULIZER

(NEBULIZER OR NEBULIZERS)

L10 4 L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZER)

=> d bib 1-4 110

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:824855 CAPLUS

DN 141:320085

TI Compositions and methods for therapy for diseases characterized by defective chloride transport

IN Fischer, Horst; Illek, Beate

PA Children's Hospital Oakland, USA

SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 982,315.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004197272	A1	20041007	US 2004-769619	20040130
	US 5972995	A	19991026	US 1997-951912	19971016
	US 6329422	B1	20011211	US 1998-174077	19981016
	EP 1669067	A2	20060614	EP 2005-17863	19981016
	EP 1669067	A3	20061122		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 2003096762	A1	20030522	US 2001-982315	20011017
PRAI	US 1997-951912	A2	19971016		
	US 1998-174077	A3	19981016		
	US 2001-982315	A2	20011017		
	EP 1998-953609	A3	19981016		

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:10237 CAPLUS

DN 136:64125

TI Enhancing therapeutic effectiveness of nitric oxide inhalation

IN Bloch, Kenneth; Ichinose, Fumito; Zapol, Warren M.

PA General Hospital Corp., USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000175	A2	20020103	WO 2001-US41102	20010622
	WO 2002000175	A3	20020815		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

McIntosh

09/982,315

CA 2414409 A1 20020103 CA 2001-2414409 20010622
AU 2001073622 A5 20020108 AU 2001-73622 20010622
EP 1301076 A2 20030416 EP 2001-952915 20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004509850 T 20040402 JP 2002-504958 20010622
CN 1635923 A 20050706 CN 2001-811886 20010622
ZA 2003000702 A 20040709 ZA 2003-702 20030127
US 2003202969 A1 20031030 US 2003-458578 20030609
US 6935334 B2 20050830
PRAI US 2000-605900 A1 20000628
WO 2001-US41102 W 20010622

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:895652 CAPLUS
DN 136:31706
TI Compositions and methods for cystic fibrosis therapy
IN Fischer, Horst; Illek, Beate
PA Children's Hospital Oakland Research Institute, USA
SO U.S., 50 pp., Cont.-in-part of U.S. 5,972,995.
CODEN: USXXAM

DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6329422	B1	20011211	US 1998-174077	19981016
	US 5972995	A	19991026	US 1997-951912	19971016
	EP 1669067	A2	20060614	EP 2005-17863	19981016
	EP 1669067	A3	20061122		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 2003096762	A1	20030522	US 2001-982315	20011017
	US 2004197272	A1	20041007	US 2004-769619	20040130
PRAI	US 1997-951912	A2	19971016		
	EP 1998-953609	A3	19981016		
	US 1998-174077	A3	19981016		
	US 2001-982315	A2	20011017		

OS MARPAT 136:31706

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:265881 CAPLUS
DN 130:306615
TI Flavonoids for cystic fibrosis therapy
IN Fischer, Horst Bernhard; Illek, Beate
PA Children's Hospital Oakland Research Institute, USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918953	A1	19990422	WO 1998-US21887	19981016
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 5972995	A	19991026	US 1997-951912	19971016
	AU 9910939	A	19990503	AU 1999-10939	19981016
	EP 1024803	A1	20000809	EP 1998-953609	19981016
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	EP 1669067	A2	20060614	EP 2005-17863	19981016
	EP 1669067	A3	20061122		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI	US 1997-951912	A	19971016		
	EP 1998-953609	A3	19981016		

09/982,315

WO 1998-US21887 W 19981016
OS MARPAT 130:306615
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib kwic hitstr 4 110

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:265881 CAPLUS
DN 130:306615
TI Flavonoids for cystic fibrosis therapy
IN Fischer, Horst Bernhard; Illek, Beate
PA Children's Hospital Oakland Research Institute, USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918953	A1	19990422	WO 1998-US21887	19981016
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 5972995	A	19991026	US 1997-951912	19971016
AU 9910939	A	19990503	AU 1999-10939	19981016
EP 1024803	A1	20000809	EP 1998-953609	19981016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1669067	A2	20060614	EP 2005-17863	19981016
EP 1669067	A3	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI US 1997-951912	A	19971016		
EP 1998-953609	A3	19981016		
WO 1998-US21887	W	19981016		

OS MARPAT 130:306615

AB . . . flavones and/or isoflavones capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compns. to a patient afflicted with cystic fibrosis and/or another condition responsive to stimulation of chloride transport.

IT 50-81-7, Ascorbic acid, biological studies 50-81-7D, Ascorbic acid, salts 56-81-5, 1,2,3-Propanetriol, biological studies 67-68-5, Dimethylsulfoxide, biological studies 74-89-5, Methylamine, biological studies 117-39-5, Quercetin 153-18-4, Rutin 156-54-7, Sodium butyrate 446-72-0, Genistein 480-44-4 486-66-8, Daidzein 487-26-3, Flavanone 487-26-3D, derivs. 490-83-5, Dehydroascorbic acid 491-80-5, Biochanin A 501-36-0, Resveratrol 520-18-3 520-36-5, Apigenin 525-82-6, Flavone 525-82-6D, derivs. 528-48-3, Fisetin 552-59-0, Prunetin 574-12-9D, derivs. 1184-78-7, Trimethylamine N-oxide 1821-12-1, 4-Phenylbutyric acid 4737-27-3D, derivs. 17306-46-6, Apigenin 7-O-neohesperidoside 23522-05-6, Taurin 89149-10-0, Deoxyspergualin 223525-13-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(flavonoids for cystic fibrosis therapy)

IT 50-81-7, Ascorbic acid, biological studies 50-81-7D, Ascorbic acid, salts 487-26-3, Flavanone 487-26-3D, derivs. 490-83-5, Dehydroascorbic acid 501-36-0, Resveratrol 4737-27-3D, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(flavonoids for cystic fibrosis therapy)


RN 50-81-7 CAPLUS

CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

McIntosh

09/982,315


Absolute stereochemistry.



RN 50-81-7 CAPLUS


CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 487-26-3 CAPLUS

CN 4H-1-Benzopyran-4-one, 2,3-dihydro-2-phenyl- (CA INDEX NAME)



RN 487-26-3 CAPLUS


CN 4H-1-Benzopyran-4-one, 2,3-dihydro-2-phenyl- (CA INDEX NAME)



RN 490-83-5 CAPLUS

CN L-threo-2,3-Hexodiulosonic acid, γ -lactone (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501-36-0 CAPLUS

CN 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.

McIntosh

09/982,315



RN 4737-27-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1 STRUCTURE UPLOADED
L2 2160 S L1 FULL
E RESVERATROL/CN
L3 1 S E3
E ASCORBIC ACID/CN
L4 2 S E3
E DEHYDROASCORBIC ACID/CN
L5 2 S E3
E ASCORBATE/CN
L6 1 S E3
E ASCORBATE SALT/CN

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

L7 362 S L2 AND (L3 OR L4 OR L5 OR L6)
L8 9 S L7 AND PULMONARY
L9 2 S L7 AND AEROSOL
L10 4 S L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZE

=> s l7 and nebulizer

3591 NEBULIZER
677 NEBULIZERS
3797 NEBULIZER
(NEBULIZER OR NEBULIZERS)
L11 0 L7 AND NEBULIZER

=> s l7 and asthma

34280 ASTHMA
22 ASTHMAS
34288 ASTHMA
(ASTHMA OR ASTHMAS)
L12 2 L7 AND ASTHMA

=> d bib 1-2 l12

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:34293 CAPLUS
DN 146:135598
TI Nrf2-based compositions and methods for the treatment or prevention of disorders relating to oxidative stress
IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy, Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh, Anju

McIntosh

09/982,315

PA The Johns Hopkins University, USA
SO PCT Int. Appl., 249pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007005879	A2	20070111	WO 2006-US26056	20060703
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-696485P	P	20050701		
	US 2006-800975P	P	20060517		

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:824855 CAPLUS
DN 141:320085
TI Compositions and methods for therapy for diseases characterized by defective chloride transport
IN Fischer, Horst; Illek, Beate
PA Children's Hospital Oakland, USA
SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 982,315.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004197272	A1	20041007	US 2004-769619	20040130
	US 5972995	A	19991026	US 1997-951912	19971016
	US 6329422	B1	20011211	US 1998-174077	19981016
	EP 1669067	A2	20060614	EP 2005-17863	19981016
	EP 1669067	A3	20061122		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 2003096762	A1	20030522	US 2001-982315	20011017
PRAI	US 1997-951912	A2	19971016		
	US 1998-174077	A3	19981016		
	US 2001-982315	A2	20011017		
	EP 1998-953609	A3	19981016		

126 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1977:83869 CAPLUS
 DN 86:83869
 TL Prevention of PGF_{2α}-induced bronchoconstriction by ascorbic acid in
 asthmatic patients
 AU Blanco, S.; Robuschi, M.; Grugni, A.; Allegra, L.
 CS Clin. Tisiol. Mal. Appar. Respir., Milan, Italy
 SO IRES Medical Science: Library Compendium 1977, 5(1), 33
 CODEN: IRLCD2; ISSN: 0305-6651
 DT Journal
 LA English

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1 STRUCTURE UPLOADED
 L2 2160 S L1 FULL
 E RESVERATROL/CN
 L3 1 S E3
 E ASCORBIC ACID/CN
 L4 2 S E3
 E DEHYDROASCORBIC ACID/CN
 L5 2 S E3
 E ASCORBATE/CN
 L6 1 S E3
 E ASCORBATE SALT/CN

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

L7 362 S L2 AND (L3 OR L4 OR L5 OR L6)
 L8 9 S L7 AND PULMONARY
 L9 2 S L7 AND AEROSOL
 L10 4 S L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZE
 L11 0 S L7 AND NEBULIZER
 L12 2 S L7 AND ASTHMA
 S L1 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'REGISTRY' ENTERED AT 17:50:58 ON 18 MAR 2007

L13 4 S L1

FILE 'CAPLUS' ENTERED AT 17:50:58 ON 18 MAR 2007

L14 6 S L13
 L15 6 S L14 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'CAPLUS' ENTERED AT 18:06:48 ON 18 MAR 2007

L16 0 S L7 AND PROPELLANT
 L17 0 S L7 AND INHALER
 L18 14 S L7 AND LUNG
 L19 86667 S L3 OR L4 OR L5 OR L6
 L20 362 S L2 AND L19
 L21 155 S L19 AND ASTHMA
 L22 221 S L19 AND AEROSOL
 L23 2 S L7 AND AEROSOL
 L24 12 S L2 AND AEROSOL
 L25 21 S L2 AND ASTHMA
 L26 23 S L21 AND L22

09/982,315

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'CAPLUS' AT 18:06:40 ON 18 MAR 2007
FILE 'CAPLUS' ENTERED AT 18:06:40 ON 18 MAR 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.88	280.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.80

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.88	280.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.80

FILE 'CAPLUS' ENTERED AT 18:06:48 ON 18 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Mar 2007 VOL 146 ISS 13
FILE LAST UPDATED: 16 Mar 2007 (20070316/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1 STRUCTURE UPLOADED
L2 2160 S L1 FULL
E RESVERATROL/CN
L3 1 S E3
E ASCORBIC ACID/CN
L4 2 S E3
E DEHYDROASCORBIC ACID/CN
L5 2 S E3
E ASCORBATE/CN
L6 1 S E3
E ASCORBATE SALT/CN

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

McIntosh

09/982,315

L7 362 S L2 AND (L3 OR L4 OR L5 OR L6)
L8 9 S L7 AND PULMONARY
L9 2 S L7 AND AEROSOL
L10 4 S L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZE
L11 0 S L7 AND NEBULIZER
L12 2 S L7 AND ASTHMA
S L1 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'REGISTRY' ENTERED AT 17:50:58 ON 18 MAR 2007
L13 4 S L1

FILE 'CAPLUS' ENTERED AT 17:50:58 ON 18 MAR 2007
L14 6 S L13
L15 6 S L14 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'CAPLUS' ENTERED AT 18:06:48 ON 18 MAR 2007

=> s l7 and propellant
21342 PROPELLANT
21249 PROPELLANTS
26756 PROPELLANT
(PROPELLANT OR PROPELLANTS)
L16 0 L7 AND PROPELLANT

=> s l7 and inhaler
2016 INHALER
2059 INHALERS
3028 INHALER
(INHALER OR INHALERS)
L17 0 L7 AND INHALER

=> s l7 and lung
193830 LUNG
44063 LUNGS
208387 LUNG
(LUNG OR LUNGS)
L18 14 L7 AND LUNG

=> d bib abs 1-14 l18

L18 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:61185 CAPLUS
DN 146:169320
TI Compositions for treating or preventing obesity, insulin resistance and
mitochondrial-associated disorders
IN Milburn, Michael; Milne, Jill; Auwerx, Johan; Argmann, Carmen; Lagouge,
Marie; Dipp, Michelle
PA Sirtris Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 337pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008548	A2	20070118	WO 2006-US26272	20060707
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-697443P	P	20050707		
	US 2005-736528P	P	20051114		
	US 2005-753606P	P	20051223		
	US 2006-783802P	P	20060316		

AB Provided herein are methods and compns. for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2.

McIntosh

Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide. Resveratrol increases the PGC-1 protein deacetylation.

L18 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:34293 CAPLUS
 DN 146:135598
 TI Nrf2-based compositions and methods for the treatment or prevention of disorders relating to oxidative stress
 IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy, Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh, Anju
 PA The Johns Hopkins University, USA
 SO PCT Int. Appl., 249pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005879	A2	20070111	WO 2006-US26056	20060703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-696485P	P	20050701		
US 2006-800975P	P	20060517		

AB The invention discloses methods for treating or preventing conditions, diseases, or disorders related to oxidative stress. In one embodiment, the method increases Nrf2 biol. activity or expression. In particular, the invention provides for the treatment or prevention of diseases relating to oxidative stress including emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia and neurodegenerative disorders, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia, cognitive deficits and neurodegenerative disorders.

L18 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1279474 CAPLUS
 DN 146:39038
 TI Compositions comprising nebivolol for the treatment of cardiovascular diseases
 IN Davis, Eric; O'Donnell, John; Bottini, Peter Bruce; Mason, Preston; Shaw, Andrew Preston
 PA Mylan Laboratories, Inc., USA
 SO PCT Int. Appl., 112pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006130174	A2	20061207	WO 2005-US41275	20051116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2005272810	A1	20051208	US 2005-141235	20050531
PRAI US 2005-141235	A	20050531		

09/982,315

US 2005-272562 A 20051110
US 2005-273992 A 20051115
US 2004-577423P P 20040604

AB Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent. There were significant concentration dependent effects on the ability of nebivolol to enhance NO release from human endothelial cells that had been chronically treated with ACE inhibitors. Addnl., this property of the drug appears to work independently of β 1-adrenoceptor blockade.

L18 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:956792 CAPLUS

DN 145:299737

TI Composition for improving skin, hair and coat health containing flavanones

IN Richelle, Myriam; Offord-Cavin, Elizabeth; Bortlik, Karlheinz;

Bureau-Franz, Isabelle; Williamson, Gary; Nielsen, Inge Lise; Steiling, Heike; Moodycliffe, Angus

PA Nestec S.A., Switz.

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058255	A1	20050630	WO 2004-EP14416	20041217
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1543810	A1	20050622	EP 2003-29183	20031218
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	AU 2004298356	A1	20050630	AU 2004-298356	20041217
	CA 2549509	A1	20050630	CA 2004-2549509	20041217
	CN 1893909	A	20070110	CN 2004-80037849	20041217
	EP 1750651	A1	20070214	EP 2004-804019	20041217
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	NO 2006003200	A	20060912	NO 2006-3200	20060710
PRAI	EP 2003-29183	A	20031218		
	WO 2004-EP14416	W	20041217		

AB The present invention pertains to a composition for preventing, decreasing and/or treating skin and hair/coat disorders, such as is effected by inflammatory reactions, environmental factors, aging or cancer. In particular, the present invention relates to the use of flavanones compds. or their derivs. in nutritional, cosmetic or pharmaceutical compns. for improvement of human or pet animal skin and coat conditions. For example, mineral water was prepared by adding hesperetin-7-glucose, in an amount of 0.01 mg to 200 mg per L, estimating that the average consumption is of about 1 L per day.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:796329 CAPLUS

DN 145:224864

TI Hydroxylated nebivolol metabolites for treating and/or preventing vascular diseases

IN O'Donnell, John P.; Owens, Walter; Duncan, Joseph; Shaw, Andrew; Wu, Jinn

PA Mylan Laboratories, Inc., USA

SO PCT Int. Appl., 120pp.

CODEN: PIXXD2

DT Patent

McIntosh

09/982,315

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006083779	A2	20060810	WO 2006-US3252	20060130
	WO 2006083779	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2007014733	A1	20070118	US 2006-342497	20060130
PRAI US 2005-648551P	P	20050131		
US 2006-755856P	P	20060103		

AB Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preps. in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6'-difluoro-, 4-hydroxy-5-phenol-6,6'-difluoro-, and 4-hydroxy-8-phenol-6,6'-difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compns. comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one addnl. compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders. Thus, acute treatment with six stereoselective hydroxy metabolites in endothelial cells from both white and black American donors showed that all six hydroxy metabolites have activity that was much superior to d-nebivolol, and most are superior to nebivolol racemate. As compared to nebivolol, the 4'-(R)-hydroxy-7-fluoro-6-hydroxy-1-nebivolol metabolite caused a nearly two-fold increase in NO release to 476 ± 20 and 383 ± 18 nmol/L, resp., from white and black donors. The 4'-(R)-hydroxy-5-fluoro-1-nebivolol metabolite also exceeded the activity of nebivolol and even l-nebivolol by >50%. These findings indicate that hydroxy metabolites of nebivolol have distinct and highly reproducible effects on acute NO release in human endothelial cells.

L18 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:606492 CAPLUS

DN 145:76623

TI Compounds and methods for thiol-containing compound efflux and cancer treatment

IN Day, Brian J.; Kachadourian, Remy

PA National Jewish Medical and Research Center, USA

SO U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of U.S. Ser. No. 400,980.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006135585	A1	20060622	US 2005-280959	20051115
	US 2004087527	A1	20040506	US 2003-400980	20030327
PRAI	US 2002-422802P	P	20021031		
	US 2003-400980	A2	20030327		

OS MARPAT 145:76623

AB Methods for therapy of cystic fibrosis and other conditions such as cancer are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compds. within the

McIntosh

09/982,315

cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis, cancer and/or another condition responsive to stimulation of thiol-containing compound transport.

L18 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:211502 CAPLUS
DN 144:267270
TI Fused bicyclic natural compounds and their use as inhibitors of PARP and PARP-mediated inflammatory processes
IN Hageman, Gerrigje Johanna; Moonen, Harald Johan Joseph; Geraets, Liesbeth; Bast, Aalt; Wouters, Emiel Frans Maria
PA Stichting voor de Technische Wetenschappen, Neth.
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006024545	A1	20060309	WO 2005-EP9514	20050905
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2004-447196	A	20040903		
	EP 2004-447238	A	20041028		
OS	MARPAT 144:267270				

AB The invention relates to the use of at least two compds., of which the first compound is a natural compound such as xanthines, coumarins, flavonoids, and anthocyanidins which are identified as PARP-1 (poly(ADP-ribose) polymerase 1) inhibitors and a second compound, which is an NAD+ precursor for preparing medicaments, medical foods or nutraceuticals. The invention also relates to the use of these compds. or pharmaceutical compns. comprising at least two of these compds. as anti-inflammatory agent for treating acute or chronic inflammation in certain diseases or disorders.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:964594 CAPLUS
DN 141:406143
TI Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism
IN Riordan, Neil H.
PA USA
SO U.S. Pat. Appl. Publ., 18 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004223962	A1	20041111	US 2003-647131	20030822
	WO 2004100879	A2	20041125	WO 2004-US14010	20040505
	WO 2004100879	A3	20050909		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1631303	A2	20060308	EP 2004-751406	20040505

McIntosh

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 US 2006222641 A1 20061005 US 2006-452695 20060614
 PRAI US 2003-468948P P 20030507
 US 2003-647131 A 20030822
 WO 2004-US14010 W 20040505
 AB The present invention relates to a composition and method for preventing or reducing edema, deep vein thrombosis (DVT), and/or pulmonary embolism by administering a combination of a fibrinolytic agent and an antioxidant. The composition is particularly useful for treating individuals prior to or during long term flights or other situations involving extended immobility.

L18 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:824855 CAPLUS
 DN 141:320085
 TI Compositions and methods for therapy for diseases characterized by defective chloride transport
 IN Fischer, Horst; Illek, Beate
 PA Children's Hospital Oakland, USA
 SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 982,315.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004197272	A1	20041007	US 2004-769619	20040130
US 5972995	A	19991026	US 1997-951912	19971016
US 6329422	B1	20011211	US 1998-174077	19981016
EP 1669067	A2	20060614	EP 2005-17863	19981016
EP 1669067	A3	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2003096762	A1	20030522	US 2001-982315	20011017
PRAI US 1997-951912	A2	19971016		
US 1998-174077	A3	19981016		
US 2001-982315	A2	20011017		
EP 1998-953609	A3	19981016		

AB Compns. and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compns. comprise one or more compds. such as flavones and/or isoflavones, ascorbate and/or derivs. thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compns. to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport. For example, L-ascorbic acid was found to be able to stimulate the CFTR activity through a cAMP mediated pathway.

L18 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:490332 CAPLUS
 DN 141:48496
 TI Reporter gene systems for the identification of compounds inducing genes of xenobiotic and drug metabolism
 IN Raucy, Judy
 PA USA
 SO U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 832,621.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004115627	A1	20040617	US 2002-222679	20020816
WO 2001079845	A1	20011025	WO 2001-US11819	20010411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

09/982,315

US 2002168623 A1 20021114 US 2001-832621 20010411
WO 2004016759 A2 20040226 WO 2003-US25619 20030815
WO 2004016759 A3 20040401

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003262720 A1 20040303 AU 2003-262720 20030815
US 2004077080 A1 20040422 US 2003-642322 20030815

PRAI US 2000-196681P P 20000412
US 2000-241391P P 20001017
US 2001-832621 A2 20010411
WO 2001-US11819 A 20010411
US 2002-222679 A 20020816
WO 2003-US25619 W 20030815

AB Reporter gene systems that are inducible by xenobiotics are described for use in the screening of xenobiotics and drugs for their ability to induce expression of genes for xenobiotic or drug metabolism. In particular, the method is used to screen for inducers of expression of the gene for cytochrome CYP3A4. The system uses a gene for a receptor or transcription factor responsive to xenobiotics and a reporter gene under control of a promoter regulated by the receptor or transcription factor. The method can also be used to assay the effectiveness of a compound, such as a drug, as an inducer of expression from xenobiotic-dependent promoters. This method can be adapted to high throughput screening. Use of the promoter of the CYP3A4 gene to drive expression of a luciferase reporter gene is demonstrated. The gene was inducible by xenobiotics including TCDD and a number of dietary flavonoids.

L18 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:331687 CAPLUS

DN 140:351644

TI Reporter gene systems for the identification of compounds inducing genes of xenobiotic metabolism

IN Raucy, Judy

PA USA

SO U.S. Pat. Appl. Publ., 91 pp., Cont.-in-part of U.S. Ser. No. 222,679.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004077080	A1	20040422	US 2003-642322	20030815
	US 2002168623	A1	20021114	US 2001-832621	20010411
	US 2004115627	A1	20040517	US 2002-222679	20020816
PRAI	US 2000-196681P	P	20000412		
	US 2000-241391P	P	20001017		
	US 2001-832621	A2	20010411		
	US 2002-222679	A2	20020816		
	WO 2001-US11819	A	20010411		

AB Transgenic cells which may be used to test xenobiotics for induction of genes encoding xenobiotic-metabolizing enzymes are disclosed. The system uses a gene for a receptor or transcription factor responsive to xenobiotics and a reporter gene under control of a promoter regulated by the receptor or transcription factor. This method can be adapted to high throughput screening. Thus, HepG2 and Caco2 cell lines were stably transformed with a vector encoding PXR as well as another vector containing the firefly luciferase gene under control of PXR-binding MDR1 promoter elements. Luciferase gene induction was observed in response to rifampicin, dexamethasone, mevastatin, mifepristone, omeprazole, kava-kava, chrysin, 2-AAF, and methoxychlor.

L18 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:162791 CAPLUS

DN 140:212007

TI Reporter gene systems for the identification of compounds inducing genes of xenobiotic metabolism

IN Raucy, Judy

McIntosh

09/982,315

PA USA
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016759	A2	20040226	WO 2003-US325619	20030815
	WO 2004016759	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004115627	A1	20040617	US 2002-222679	20020816
	AU 2003262720	A1	20040303	AU 2003-262720	20030815
PRAI	US 2002-222679	A	20020816		
	US 2000-196681P	P	20000412		
	US 2000-241391P	P	20001017		
	US 2001-832621	A2	20010411		
	WO 2001-US11819	A	20010411		
	WO 2003-US25619	W	20030815		

AB Reporter gene systems that are inducible by xenobiotics are described for use in the screening of xenobiotics for their ability to induce gene expression. The system uses a gene for a receptor or transcription factor responsive to xenobiotics and a reporter gene under control of a promoter regulated by the receptor or transcription factor. The method can also be used to assay the effectiveness of a compound, such as a drug, as an inducer of expression from xenobiotic-dependent promoters. This method can be adapted to high throughput screening.

L18 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:10237 CAPLUS
DN 136:64125
TI Enhancing therapeutic effectiveness of nitric oxide inhalation
IN Bloch, Kenneth; Ichinose, Fumito; Zapol, Warren M.
PA General Hospital Corp., USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000175	A2	20020103	WO 2001-US41102	20010622
	WO 2002000175	A3	20020815		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2414409	A1	20020103	CA 2001-2414409	20010622
	AU 2001073622	A5	20020108	AU 2001-73622	20010622
	EP 1301076	A2	20030416	EP 2001-952915	20010622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004509850	T	20040402	JP 2002-504958	20010622
	CN 1635923	A	20050706	CN 2001-811886	20010622
	ZA 2003000702	A	20040709	ZA 2003-702	20030127
	US 2003202969	A1	20031030	US 2003-458578	20030609
	US 6935334	B2	20050830		
PRAI	US 2000-605900	A1	20000628		
	WO 2001-US41102	W	20010622		

AB Methods for reducing, partially preventing or completely preventing nitric oxide (NO) inhalation-related impairment of hypoxic pulmonary

vasoconstriction (HPV) in a mammal are disclosed. The methods include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-reactive oxygen species (anti-ROS) agent, e.g., N-acetyl-cysteine, or a leukotriene blocker. Methods for reducing, partially preventing or completely preventing loss of pulmonary vasodilatory responsiveness to NO inhalation in a mammal are also disclosed. The methods include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti ROS agent a therapeutically effective amount of a leukotriene blocker.

L18 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:708961 CAPLUS
 DN 129:335781
 TI Stabilized medicaments containing cysteinyl derivatives
 IN Stanislaus, Fritz
 PA Klinge Pharma G.m.b.H., Germany
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 PAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847534	A1	19981029	WO 1997-EP1941	19970418
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9723879	A	19981113	AU 1997-23879	19970418
	EP 971743	A1	20000119	EP 1997-919382	19970418
	EP 971743	B1	20060712		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001524087	T	20011127	JP 1998-544767	19970418
	AT 332709	T	20060815	AT 1997-919382	19970418
	US 2002037855	A1	20020328	US 2001-816769	20010322
	US 2003119909	A1	20030626	US 2002-227186	20020821
PRAI	US 2000-403160	B1	20000505		
	EP 1997-919382	A	19970418		
	WO 1997-EP1941	A	19970418		
	US 2001-816769	B1	20010322		

not Pub. in English

AB The antiinflammatory activity of NSAIDs is synergistically enhanced by combination with cysteine derivs., especially glutathione or N-acetylcysteine. The stability of these combinations is improved by addition of ≥ 3 antioxidants selected from (a) ascorbic acid or its salts or esters, (b) ≥ 1 tocopherol, (c) ≥ 1 carotenoid and/or vitamin A, and (d) ≥ 1 flavonoid, flavanol, catechol, or anthocyanin or their glycosides. The combinations may be formulated e.g. as effervescent tablets.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1	STRUCTURE UPLOADED
L2	2160 S L1 FULL
	E RESVERATROL/CN
L3	1 S E3
	E ASCORBIC ACID/CN
L4	2 S E3
	E DEHYDROASCORBIC ACID/CN
L5	2 S E3
	E ASCORBATE/CN
L6	1 S E3
	E ASCORBATE SALT/CN

09/982,315

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

L7 362 S L2 AND (L3 OR L4 OR L5 OR L6)
L8 9 S L7 AND PULMONARY
L9 2 S L7 AND AEROSOL
L10 4 S L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZE
L11 0 S L7 AND NEBULIZER
L12 2 S L7 AND ASTHMA
S L1 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'REGISTRY' ENTERED AT 17:50:58 ON 18 MAR 2007

L13 4 S L1

FILE 'CAPLUS' ENTERED AT 17:50:58 ON 18 MAR 2007

L14 6 S L13
L15 6 S L14 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'CAPLUS' ENTERED AT 18:06:48 ON 18 MAR 2007

L16 0 S L7 AND PROPELLANT
L17 0 S L7 AND INHALER
L18 14 S L7 AND LUNG

=> s 13 or 14 or 15 or 16

MISSING OPERATOR L5 LOR

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s 13 or 14 or 15 or 16

2961 L3
83031 L4
3153 L5
297 L6
L19 86667 L3 OR L4 OR L5 OR L6

=> s 12 and 119

8642 L2
L20 362 L2 AND L19

=> s 119 and asthma

34280 ASTHMA
22 ASTHMAS
34288 ASTHMA
(ASTHMA OR ASTHMAS)
L21 155 L19 AND ASTHMA

=> s 119 and aerosol

61419 AEROSOL
50350 AEROSOLS
76171 AEROSOL
(AEROSOL OR AEROSOLS)
L22 221 L19 AND AEROSOL

=> s 17 and aerosol

61419 AEROSOL
50350 AEROSOLS
76171 AEROSOL
(AEROSOL OR AEROSOLS)
L23 2 L7 AND AEROSOL

=> d bib 123

L23 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:34293 CAPLUS

DN 146:135598

TI Nrf2-based compositions and methods for the treatment or prevention of
disorders relating to oxidative stress

IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy,
Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh,
Anju

PA The Johns Hopkins University, USA

SO PCT Int. Appl., 249pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

McIntosh

09/982,315

PI WO 2007005879 A2 20070111 WO 2006-US26056 20060703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
PRAI US 2005-696485P P 20050701
US 2006-800975P P 20060517

=> d bib 123 2

L23 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:376557 CAPLUS
DN 138:367907
TI Nutritional supplements and methods for prevention, reduction and
treatment of radiation injury
IN Rosenbloom, Richard A.
PA The Quigley Corporation, USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003039452	A2	20030515	WO 2002-US13526	20020501
	WO 2003039452	A3	20041202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003103953	A1	20030605	US 2001-993003	20011106
	US 6753325	B2	20040622		
	US 2003103954	A1	20030605	US 2002-45790	20020114
	US 2003105027	A1	20030605	US 2002-132642	20020425
	CA 2465945	A1	20030515	CA 2002-2465945	20020501
	EP 1505984	A2	20050216	EP 2002-736624	20020501
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005510509	T	20050421	JP 2003-541744	20020501
	IN 2004DN01165	A	20060728	IN 2004-DN1165	20040430
PRAI	US 2001-993003	A	20011106		
	US 2002-45790	A	20020114		
	US 2002-132642	A	20020425		
	WO 2002-US13526	W	20020501		

=> s 12 and aerosol

8642 L2
61419 AEROSOL
50350 AEROSOLS
76171 AEROSOL
(AEROSOL OR AEROSOLS)

L24 12 L2 AND AEROSOL

=> d bib 1-12 124

L24 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:193509 CAPLUS
DN 146:235430
TI .Hair-and-scalp cosmetics containing cell activators, blood circulation

McIntosh

09/982,315

improvers, antiinflammatory agents, antibacterial agents, and/or local stimulants

IN Sato, Maruyasu
PA Lion Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 25pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2007045712	A	20070222	JP 2005-228753	20050805
PRAI	JP 2005-228753		20050805		

L24 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:34293 CAPLUS

DN 146:135598

TI Nrf2-based compositions and methods for the treatment or prevention of disorders relating to oxidative stress

IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy, Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh, Anju

PA The Johns Hopkins University, USA

SO PCT Int. Appl., 249pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007005879	A2	20070111	WO 2006-US26056	20060703
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-696485P	P	20050701		
	US 2006-800975P	P	20060317		

L24 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:17801 CAPLUS

DN 146:106832

TI Sunless tanning composition comprising dihydroacetone and an amphoglycinat

IN Dueva-Koganov, Olga; Russo, Thomas; Sanogueira, James P.

PA USA

SO U.S. Pat. Appl. Publ., 12pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007003496	A1	20070104	US 2005-174044	20050701
	WO 2007005741	A2	20070111	WO 2006-US25830	20060630
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-174044	A	20050701		

McIntosh

09/982,315

OS MARPAT 146:106832

L24 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:530596 CAPLUS
DN 145:50991
TI Echinacea purpurea honey and its application in oral liquid
IN Ye, Hongping; Zhu, Zuolin; Sun, Meng
PA Huaibei Huike Pharmaceutical Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shengqing Gongkai Shuomingshu, 12 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1778315	A	20060531	CN 2005-10071590	20050528
	WO 2006128335	A1	20061207	WO 2005-CN1756	20051024
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	CN 2005-10071590	A	20050528		

L24 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1103333 CAPLUS
DN 143:373354
TI Cholesterol lowering combination containing a flavonoid, phytosterol and tocotrienol
IN Guthrie, Najla
PA KGK Synergize Inc., Can.
SO U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005227930	A1	20051013	US 2005-102278	20050408
	WO 2005096704	A2	20051020	WO 2005-IB929	20050408
	WO 2005096704	A3	20060406		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2004-560284P	P	20040408		

L24 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:648553 CAPLUS
DN 143:179577
TI Antidepressant medical compositions containing Chinese medicines extracted from herbs
IN Shi, Renbing; Liu, Bin; Wang, Qingguo; Li, Jun; Chang, Hongsheng
PA Beijing University of Chinese Medicine, Peop. Rep. China
SO Faming Zhuanli Shengqing Gongkai Shuomingshu, 28 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

McIntosh

PI	CN 1416881	A	20030514	CN 2002-153313	20021127
PRAI	CN 2002-153313		20021127		

L24 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:66545 CAPLUS
 DN 140:133827
 TI Nutraceutical antiviral and antioxidant compositions containing lead-free propolis extracts and/or their inclusion complexes with cyclodextrin
 IN Jiang, Deyong
 PA Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 22 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1342464	A	20020403	CN 2001-141763	20010918
PRAI	CN 2001-141763		20010918		

L24 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:376557 CAPLUS
 DN 138:367907
 TI Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
 IN Rosenbloom, Richard A.
 PA The Quigley Corporation, USA
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003039452	A2	20030515	WO 2002-US13526	20020501
	WO 2003039452	A3	20041202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003103953	A1	20030605	US 2001-993003	20011106
	US 6753325	B2	20040622		
	US 2003103954	A1	20030605	US 2002-45790	20020114
	US 2003105027	A1	20030605	US 2002-132642	20020425
	CA 2465945	A1	20030515	CA 2002-2465945	20020501
	EP 1505984	A2	20050216	EP 2002-736624	20020501
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005510509	T	20050421	JP 2003-541744	20020501
	IN 2004DN01165	A	20060728	IN 2004-DN1165	20040430
PRAI	US 2001-993003	A	20011106		
	US 2002-45790	A	20020114		
	US 2002-132642	A	20020425		
	WO 2002-US13526	W	20020501		

L24 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:107102 CAPLUS
 DN 136:145285
 TI Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
 IN Berg, Kurt Frimann
 PA Immunopharm Aps, Den.
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

09/982,315

PI WO 2002009699 A2 20020207 WO 2001-DK515 20010723
WO 2002009699 A3 20030103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, NZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2416899 A1 20020207 CA 2001-2416899 20010723
EP 1307189 A2 20030507 EP 2001-957764 20010723
EP 1307189 B1 20060510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004505046 T 20040219 JP 2002-515252 20010723
BR 2001012818 A 20041019 BR 2001-12818 20010723
NZ 524121 A 20050930 NZ 2001-524121 20010723
AT 325612 T 20060615 AT 2001-957764 20010723
NO 2003000337 A 20030321 NO 2003-337 20030122
ZA 2003000723 A 20040428 ZA 2003-723 20030127
US 2004053858 A1 20040318 US 2003-363430 20030922
US 7166640 B2 20070123
HK 1057330 A1 20061222 HK 2003-108112 20031107
US 2005245467 A1 20051103 US 2005-172878 20050705
PRAI DK 2000-1152 A 20000728
DK 2000-1316 A 20000904
DK 2000-1935 A 20001223
DK 2001-7 A 20010103
DK 2001-827 A 20010522
WO 2001-DK515 W 20010723
US 2003-363430 A1 20030922
OS MARPAT 136:145285

L24 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:443805 CAPLUS
DN 135:361665
TI Identification and emission factors of molecular tracers in organic
aerosols from biomass burning. Part 1. Temperate climate conifers
AU Oros, D. R.; Simoneit, B. R. T.
CS College of Oceanic and Atmospheric Sciences, Environmental and Petroleum
Geochemistry Group, Oregon State University, Corvallis, OR, 97331, USA
SO Applied Geochemistry (2001), 16(13), 1513-1544
CODEN: APPGEY; ISSN: 0883-2927
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:50468 CAPLUS
DN 134:110442
TI Use of flavones, coumarins and related compounds to treat infections
IN Prendergast, Patrick T.
PA Ire.
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001003681	A2	20010118	WO 2000-IB1039	20000707
	WO 2001003681	A3	20020510		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				

09/982,315

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2375647 A1 20010118 CA 2000-2375647 20000707
EP 1223928 A2 20020724 EP 2000-948187 20000707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 2003504327 T 20030204 JP 2001-508962 20000707
US 6555523 B1 20030429 US 2000-612025 20000707
PRAI US 1999-142894P P 19990708
US 1999-163089P P 19991102
WO 2000-IB1039 W 20000707
OS MARPAT 134:110442

L24 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1962:483676 CAPLUS
DN 57:83676
OREF 57:16765b-c
TI Steroid-flavone compositions
IN Schlagel, Carl A.
PA Upjohn Co.
SO 21 pp.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 613613		19620807	BE	
	FR M1751			FR	
	GB 928150			GB	
PRAI	US		19610208		
OS	MARPAT 57:83676				

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1 STRUCTURE UPLOADED
L2 2160 S L1 FULL
E RESVERATROL/CN
L3 1 S E3
E ASCORBIC ACID/CN
L4 2 S E3
E DEHYDROASCORBIC ACID/CN
L5 2 S E3
E ASCORBATE/CN
L6 1 S E3
E ASCORBATE SALT/CN

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

L7 362 S L2 AND (L3 OR L4 OR L5 OR L6)
L8 9 S L7 AND PULMONARY
L9 2 S L7 AND AEROSOL
L10 4 S L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZE
L11 0 S L7 AND NEBULIZER
L12 2 S L7 AND ASTHMA
S L1 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'REGISTRY' ENTERED AT 17:50:58 ON 18 MAR 2007

L13 4 S L1

FILE 'CAPLUS' ENTERED AT 17:50:58 ON 18 MAR 2007

L14 6 S L13
L15 6 S L14 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'CAPLUS' ENTERED AT 18:06:48 ON 18 MAR 2007

L16 0 S L7 AND PROPELLANT
L17 0 S L7 AND INHALER
L18 14 S L7 AND LUNG
L19 86667 S L3 OR L4 OR L5 OR L6
L20 362 S L2 AND L19
L21 155 S L19 AND ASTHMA
L22 221 S L19 AND AEROSOL
L23 2 S L7 AND AEROSOL
L24 12 S L2 AND AEROSOL

McIntosh

09/982,315

=> s 12 and asthma

8642 L2
34280 ASTHMA
22 ASTHMAS
34288 ASTHMA

(ASTHMA OR ASTHMAS)

L25 21 L2 AND ASTHMA

=> d bib 1-21 125

L25 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:34293 CAPLUS

DN 146:135598

TI Nrf2-based compositions and methods for the treatment or prevention of disorders relating to oxidative stress

IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy, Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh, Anju

PA The Johns Hopkins University, USA

SO PCT Int. Appl., 249pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007005879	A2	20070111	WO 2006-US26056	20060703
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2005-696485P	P	20050701		
US 2006-800975P	P	20060517		

L25 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:805219 CAPLUS

DN 145:271536

TI Isoflavanone derivatives which have Il-5 activity inhibiting activity, method for manufacturing the same and use thereof as Il-5 inhibitor

IN Jung, Sang Heon; Kim, Mi Gyeong; Kim, Yeong Su; Lee, Seung Ho; Ryu, Jae Cheon

PA The Industry & Academic Cooperation In Chungnam National University (Iac), S. Korea

SO Repub. Korean Kongkae Taeho Kongbo, No pp. given

CODEN: KRXXA7

DT Patent

LA Korean

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI KR 2004093500	A	20041106	KR 2003-27369	20030430
PRAI KR 2003-27369		20030430		

L25 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:11300 CAPLUS

DN 144:108195

TI Preparation of tetracyclic compounds as estrogen ligands

IN Miller, Christopher P.; Collini, Michael D.; Morris, Robert L.; Singhaus, Robert R.

PA Wyeth, John, and Brother Ltd., USA

SO U.S. Pat. Appl. Publ., 33 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

McIntosh

PI	US 2006004087	A1	20060105	US 2005-170017	20050629
	AU 2005262385	A1	20060119	AU 2005-262385	20050629
	CA 2570518	A1	20060119	CA 2005-2570518	20050629
	WO 2006007503	A1	20060119	WO 2005-US23044	20050629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1761513	A1	20070314	EP 2005-788764	20050629
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2004-584516P	P	20040701		
	WO 2005-US23044	W	20050629		
OS	MARPAT 144:108195				

L25 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1334474 CAPLUS
DN 144:69734
TI Preparation of flavanone derivatives as inducers of heme oxygenase or induction promoters of heme oxygenase
IN Miyaji, Hiroyuki; Eiraku, Tomohiko; Ishiguro, Hanae
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005350362	A	20051222	JP 2004-170090	20040608
PRAI	JP 2004-170090		20040608		
OS	MARPAT 144:69734				

L25 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1260614 CAPLUS
DN 143:483199
TI Treatment for asthma and arthritis and other inflammatory diseases
IN Chandler, Anthony Michael
PA Bionovate Limited, UK
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005112960	A1	20051201	WO 2005-GB1885	20050517
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2567189	A1	20051201	CA 2005-2567189	20050517
	EP 1758603	A1	20070307	EP 2005-744844	20050517
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	GB 2004-11166	A	20040519		
	WO 2005-GB1885	W	20050517		

09/982,315

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:395309 CAPLUS

DN 142:447230

TI Preparation of heterocyclic compounds including chromenones,
quinazolinones, quinolinones and pyrazolopyrimidinone that block the
effects of advanced glycation end products

IN Yeleswarapu, Koteswar Rao; Manojit, Pal; Vedula Manohar, Sharma; Akella,
Venkateswarlu; Pillarisetti, Sivaram; Padakanti, Srinivas; Kalleda,
Srinivasa Rao

PA Reddy's Laboratories Ltd., India

SO PCT Int. Appl., 212 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005040163	A1	20050506	WO 2004-IB3430	20041020
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PI, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI IN 2003-CH861

A

20031028

OS MARPAT 142:447230

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:824855 CAPLUS

DN 141:320085

TI Compositions and methods for therapy for diseases characterized by
defective chloride transport

IN Fischer, Horst; Illek, Beate

PA Children's Hospital Oakland, USA

SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 982,315.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004197272	A1	20041007	US 2004-769619	20040130
US 5972995	A	19991026	US 1997-951912	19971016
US 6329422	B1	20011211	US 1998-174077	19981016
EP 1669067	A2	20060614	EP 2005-17863	19981016
EP 1669067	A3	20061122		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
US 2003096762	A1	20030522	US 2001-982315	20011017
PRAI US 1997-951912	A2	19971016		
US 1998-174077	A3	19981016		
US 2001-982315	A2	20011017		
EP 1998-953609	A3	19981016		

L25 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:131011 CAPLUS

DN 141:391

TI Relaxant effects of flavonoids in isolated guinea pig trachea and their
structure-activity relationships

AU Ko, Wun-Chang; Liu, Pi-Ying; Chen, Junn-Lain; Leu, I-Jung; Shih,
Chwen-Ming

CS Graduate Institute of Pharmacology, College of Medicine, Taipei Medical
University, Taipei, Taiwan

SO Planta Medica (2003), 69(12), 1086-1090

CODEN: PLMEAA; ISSN: 0032-0943

McIntosh

09/982,315

PB Georg Thieme Verlag
DT Journal
LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:652131 CAPLUS

DN 139:214237

TI Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

IN Scaramuzzino, Giovanni

PA Italy

SO Eur. Pat. Appl., 313 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1336602	A1	20030820	EP 2002-425075	20020213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI EP 2002-425075 20020213

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:670444 CAPLUS

DN 137:310086

TI Flavonoid intake and risk of chronic diseases

AU Knekt, Paul; Kumpulainen, Jorma; Jarvinen, Ritva; Rissanen, Harri; Heliovaara, Markku; Reunanen, Antti; Hakulinen, Timo; Aromaa, Arpo

CS National Public Health Institute, Helsinki, 00300, Finland

SO American Journal of Clinical Nutrition (2002), 76(3), 560-568

CODEN: AJCNAC; ISSN: 0002-9165

PB American Society for Clinical Nutrition

DT Journal

LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:587510 CAPLUS

DN 138:214847

TI Natural compounds with bronchodilator activity selected by molecular topology

AU Rios-Santamarina, Imaculada; Garcia Domenech, Ramon; Cortijo, Julio; Santamaria, Pedro; Morcillo, Esteban J.; Galvez, Jorge

CS Unidad de Investigacion de Diseno de Farmacos y Conectividad Molecular, Departamento de Quimica-Fisica, Facultad de Farmacia, Universitat de Valencia, Burjassot, Valencia, 46100, Spain

SO Internet Electronic Journal of Molecular Design [online computer file] (2002), 1(2), 70-79

CODEN: IEJMAT; ISSN: 1538-6414

URL: http://biochempress.com/iejmd_2002_1_0070.pdf

PB BioChem Press

DT Journal; (online computer file)

LA English

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:529212 CAPLUS

DN 136:272967

TI Effects of absorbed components of Saiboku-to on the release of leukotrienes from polymorphonuclear leukocytes of patients with bronchial asthma

AU Niitsuma, T.; Morita, S.; Hayashi, T.; Homma, M.; Oka, K.

CS Department of Third Internal Medicine, Tokyo Medical University, Tokyo, Japan

SO Methods and Findings in Experimental and Clinical Pharmacology (2001), 23(2), 99-104

CODEN: MFEPDX; ISSN: 0379-0355

09/982,315

PB Prous Science
DT Journal
LA English

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:811996 CAPLUS
DN 134:110311
TI Pharmacological effects of urinary products obtained after treatment with
saiboku-to, a herbal medicine for bronchial asthma, on type IV
allergic reaction
AU Taniguchi, Chizu; Homma, Masato; Takano, Osamu; Hirano, Toshihiko; Oka,
Kitaro; Aoyagi, Yutaka; Niitsuma, Tomoyuki; Hayashi, Tooru
CS Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life
Science, Tokyo, Japan
SO Planta Medica (2000), 66(7), 607-611
CODEN: PLMEAA; ISSN: 0032-0943
PB Georg Thieme Verlag
DT Journal
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:124145 CAPLUS
DN 132:212562
TI Inhibitory effects of lignans and flavonoids in Saiboku-To, a herbal
medicine for bronchial asthma, on the release of leukotrienes
from human polymorphonuclear leukocytes
AU Homma, Masato; Minami, Mana; Taniguchi, Chizu; Oka, Kitara; Morita,
Sonoko; Niitsuma, Tomoyuki; Hayashi, Toru
CS Dep. Clinical Pharmacology, Tokyo Univ. Pharmacy Life Sci., Hajioji, 192,
Japan
SO Planta Medica (2000), 66(1), 88-91
CODEN: PLMEAA; ISSN: 0032-0943
PB Georg Thieme Verlag
DT Journal
LA English

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:613674 CAPLUS
DN 131:219149
TI Constituents from Ginkgo biloba leaves, preparation and uses
IN Xie, Delong; Wang, Ning; Gao, Qi; Zhang, Guoan; Shao, Baoping; Jin,
Xiaowu; Huang, Xinsheng
PA Shanghai Institute of Chinese Materia Medica (SICMM), Peop. Rep. China
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9947148	A1	19990923	WO 1999-CN38	19990319
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6030621	A	20000229	US 1998-44551	19980319
US 6187314	B1	20010213	US 1998-97058	19980612
AU 9928247	A	19991011	AU 1999-28247	19990319
AU 741628	B2	20011206		
GB 2352177	A	20010124	GB 2000-24213	19990319
GB 2352177	B	20010806		
CN 1292704	A	20010425	CN 1999-803683	19990319
CN 1508542	A	20010630	CN 2003-10118517	19990319
CN 1740786	A	20010301	CN 2005-10105217	19990319
CN 1740787	A	20010301	CN 2005-10105218	19990319

respiratory
asthma

prince

09/982,315

US 2001055629 A1 20011227 US 2001-768678 20010124
US 2003152654 A1 20030814 US 2002-268237 20021010
US 6632460 B2 20031014
PRAI US 1998-44551 A 19980319
US 1998-97058 A1 19980612
CN 1999-803683 A 19990319
CN 2003-10118517 A3 19990319
WO 1999-CN38 W 19990319
US 2001-768678 A1 20010124

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:207154 CAPLUS
DN 131:27778
TI Effects of Bakumondo-to (Mai-Men-Dong-Tang) on bronchial-asthmatic cough
and analysis of urinary-secretion components
AU Niitsuma, Tomoyuki; Tamaki, Toshikazu; Sakurai, Kahori; Maruoka, Noritaka;
Morita, Sonoko; Matsumura, Yasuhiro; Hayashi, Tohru; Taniguchi, Chizu;
Homma, Masato; Oka, Kitaro
CS 3rd Dep. Intern. Med., Tokyo Med. Univ., Tokyo, Japan
SO Kanpo to Men'eki Arerugi (1998), 12, 76-86
CODEN: KMARED; ISSN: 0914-6407
PB Fama Intanashonaru
DT Journal
LA Japanese

L25 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:513625 CAPLUS
DN 127:190650
TI Preparation of dihydropyridines, pyridines, benzopyranones, and
triazoloquinazolines for use as adenosine receptor antagonists
IN Jacobson, Kenneth A.; Jiang, Ji-Long; Kim, Yong-Chul; Karton, Yishai; Van
Rhee, Albert M.
PA United States Dept. of Health and Human Services, USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9727177	A2	19970731	WO 1997-US1252	19970129
	WO 9727177	A3	19971113		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2244774	A1	19970731	CA 1997-2244774	19970129
	CA 2244774	C	20061017		
	AU 9722466	A	19970820	AU 1997-22466	19970129
	AU 709190	B2	19990826		
	EP 885192	A1	19981223	EP 1997-905627	19970129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000516910	T	20001219	JP 1997-527065	19970129
	US 6066642	A	20000523	US 1998-117598	19981207
	AU 9957171	A1	20000217	AU 1999-57171	19991101
	AU 755525	B2	20021212		
PRAI	US 1996-10737P	P	19960129		
	US 1996-21191P	P	19960703		
	WO 1997-US1252	W	19970129		
OS	MARPAT 127:190650				

L25 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1994:289825 CAPLUS
DN 120:289825
TI A novel 11 β -hydroxysteroid dehydrogenase inhibitor contained in
Saiboku-To, a herbal remedy for steroid-dependent bronchial asthma
AU Homma, Masato; Oka, Kitaro; Niitsuma, Tomoyuki; Itoh, Hisao
CS Dep. Clin. Pharm., Tokyo Coll. Pharm., Tokyo, 192-03, Japan
SO Journal of Pharmacy and Pharmacology (1994), 46(4), 305-9

new

09/982,315

CODEN: JPPMAB; ISSN: 0022-3573

DT Journal
LA English

L25 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:187406 CAPLUS

DN 116:187406

TI A strategy for discovering biologically active compounds with high probability in traditional Chinese herb remedies: an application of Saibokuto in bronchial asthma

AU Homma, Masato; Oka, Kitaro; Yamada, Tadashi; Niitsuma, Tomoyuki; Ihto, Hisao; Takahashi, Noriyuki

CS Div. Clin. Pharmacol., Tokyo Coll. Pharm., Hachioji, 192-03, Japan

SO Analytical Biochemistry (1992), 202(1), 179-87

CODEN: ANBCA2; ISSN: 0003-2697

DT Journal
LA English

L25 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1989:185713 CAPLUS

DN 110:185713

TI Nedocromil sodium inhibits IgE- and IgG-related antigen-induced contraction in guinea pig trachea

AU Bertrand, Claude; Tschirhart, Eric; Landry, Yves

CS Lab. Neuroimmunopharmacol., Univ. Louis-Pasteur, Strasbourg I, Illkirch, F-67401, Fr.

SO International Archives of Allergy and Applied Immunology (1989), 88(4), 439-46

CODEN: IAAAAM; ISSN: 0020-5915

DT Journal
LA English

L25 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1958:18156 CAPLUS

DN 52:18156

OREF 52:3267b-d

TI Flavonoids. I Spasmolytic material in Glycyrrhiza glabra

AU Berger, H.; Holler, H.

CS Univ. Vienna

SO Scientia Pharmaceutica (1957), 25, 172-5

CODEN: SCPHA4; ISSN: 0036-8709

DT Journal
LA Unavailable

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1 STRUCTURE UPLOADED

L2 2160 S L1 FULL

E RESVERATROL/CN

L3 1 S E3

E ASCORBIC ACID/CN

L4 2 S E3

E DEHYDROASCORBIC ACID/CN

L5 2 S E3

E ASCORBATE/CN

L6 1 S E3

E ASCORBATE SALT/CN

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

L7 362 S L2 AND (L3 OR L4 OR L5 OR L6)

L8 9 S L7 AND PULMONARY

L9 2 S L7 AND AEROSOL

L10 4 S L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZE

L11 0 S L7 AND NEBULIZER

L12 2 S L7 AND ASTHMA

S L1 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'REGISTRY' ENTERED AT 17:50:58 ON 18 MAR 2007

L13 4 S L1

FILE 'CAPLUS' ENTERED AT 17:50:58 ON 18 MAR 2007

McIntosh

09/982,315

L14 6 S L13
L15 6 S L14 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'CAPLUS' ENTERED AT 18:06:48 ON 18 MAR 2007

L16 0 S L7 AND PROPELLANT
L17 0 S L7 AND INHALER
L18 14 S L7 AND LUNG
L19 86667 S L3 OR L4 OR L5 OR L6
L20 362 S L2 AND L19
L21 155 S L19 AND ASTHMA
L22 221 S L19 AND AEROSOL
L23 2 S L7 AND AEROSOL
L24 12 S L2 AND AEROSOL
L25 21 S L2 AND ASTHMA

=> L21 and L22

L21 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L21 and L22

L26 23 L21 AND L22

=> d bib 1-23 126

L26 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:34293 CAPLUS

DN 146:135598

TI Nrf2-based compositions and methods for the treatment or prevention of disorders relating to oxidative stress

IN Biswal, Shyam; Dore, Sylvain; Thimmulappa, Rajesh Kumar; Rangasamy, Tirumalai; Sakata, Yoshihito; Shah, Zahoor Ahmad; Zhuang, Hean; Singh, Anju

PA The Johns Hopkins University, USA

SO PCT Int. Appl., 249pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007005879	A2	20070111	WO 2006-US26056	20060703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-696485P	P	20050701		
US 2006-800975P	P	20060517		

L26 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:813683 CAPLUS

DN 145:235721

TI Manufacture and application of traditional Chinese medicine composition for treating asthma

IN Yang, Xiongzhi

PA Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 7pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1813881	A	20060809	CN 2005-10061804	20051205
PRAI CN 2005-10061804		20051205		

McIntosh

09/982,315

L26 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:790907 CAPLUS
DN 145:202856
TI Use of diindolylmethane-related indoles for the treatment and prevention
of respiratory syncytial virus associated conditions
IN Zeligs, Michael A.
PA Bioresponse LLC, USA
SO PCT Int. Appl., 77pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006083458	A2	20060810	WO 2005-US47537	20051230
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-640301P	P	20041230		
OS	MARPAT 145:202856				

L26 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:232146 CAPLUS
DN 144:305135
TI Carotenoid analogs or derivatives for the inhibition and amelioration of
inflammation
IN Lockwood, Samuel Fournier; O'Malley, Sean; Jackson, Henry; Nadolski, Geoff
PA USA
SO U.S. Pat. Appl. Publ., 76 pp., Cont.-in-part of U.S. Ser. No. 106,378.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006058269	A1	20060316	US 2005-214478	20050829
	US 2005261254	A1	20051124	US 2005-106378	20050414
	WO 2007027834	A1	20070308	WO 2006-US33948	20060829
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-562195P	P	20040414		
	US 2005-106378	A2	20050414		
	US 2005-214478	A	20050829		
OS	MARPAT 144:305135				

L26 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:13820 CAPLUS
DN 144:94405
TI Aerosol suspension formulations containing TG 227 ea or TG 134 a
as propellant
IN Schmelzer, Christel; Froemder, Arne
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DT Patent
LA English

McIntosh

09/982,315

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006002863	A1	20060105	US 2005-169876	20050629
	DE 102004032322	A1	20060209	DE 2004-102004032322	20040702
	DE 102005023334	A1	20061123	DE 2005-102005023334	20050517
	CA 2571519	A1	20060112	CA 2005-2571519	20050625
	WO 2006002840	A2	20060112	WO 2005-EP6865	20050625
	WO 2006002840	A3	20061116		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	DE 2004-102004032322 A		20040702		
	DE 2005-102005023334 A		20050517		
	WO 2005-EP6865 W		20050625		

L26 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1230672 CAPLUS
DN 144:74775
TI Manufacture of sprays and aerosols for treating respiratory system diseases
IN Li, Tongwei; Zhang, Jieqing; Chen, Kun; Zhang, Xiusheng
PA Beijing Xiaohuoban Biopharmaceutical Technology Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 10 pp.
CODEN: CNXXEV
DT Patent
LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1568984	A	20050126	CN 2003-150151	20030721
PRAI	CN 2003-150151		20030721		

L26 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:556995 CAPLUS
DN 143:120519
TI Aerosol for treating nitrogen oxide toxication, its application and preparation
IN Hu, Wenxiang; Bian, Zuqing; Zhang, Kangzheng; Min, Qingwang; Wang, Jianying; Tan, Shengjian; Cao, Ye; Kong, Xiangli; Wang, Jianshe; Chen, Peirang
PA Research Institute of Military Medicine, Logistics Department, General Armament Department, the Chinese People's Liberation Army, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 11 pp.
CODEN: CNXXEV
DT Patent
LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1422620	A	20030611	CN 2001-140242	20011207
PRAI	CN 2001-140242		20011207		

L26 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:483206 CAPLUS
DN 143:13391
TI Medical composition for treating bronchial asthma
IN Sun, Yong
PA Lunan Pharmaceutical Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
CODEN: CNXXEV
DT Patent
LA Chinese

FAN.CNT 1

09/982,315

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1425378	A	20030625	CN 2003-100431	20030114
PRAI	CN 2003-100431		20030114		

L26 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:471917 CAPLUS
 DN 143:1293
 TI Use of α 1-antitrypsin compositions for treatment of pulmonary diseases
 IN Durrani, Manzer J.; Kumar, Harish; Kreiger, Timothy; Kabingue, Ken; Mosher, Virginia; Barr, Philip J.; Bathurst, Ian C.
 PA Baxter International Inc., USA; Baxter Healthcare S. A.; Arriva Pharmaceuticals Inc.
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005048985	A2	20050602	WO 2004-US38650	20041111
	WO 2005048985	A3	20060323		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004290587	A1	20050602	AU 2004-290587	20041111
	CA 2545855	A1	20050602	CA 2004-2545855	20041111
	EP 1684719	A2	20060802	EP 2004-811377	20041111
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
PRAI	US 2003-520549P	P	20031114		
	WO 2004-US38650	W	20041111		

L26 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:371100 CAPLUS
 DN 142:423841
 TI Guanosine-rich oligonucleotides for inhibiting NF κ B signaling and treatment of disease
 IN Bates, Paula J.; Girvan, Allicia C.; Barve, Shirish S.
 PA University of Louisville Research Foundation, Inc., USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037323	A2	20050428	WO 2004-US33185	20041008
	WO 2005037323	A3	20050818		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005187176	A1	20050825	US 2004-961479	20041008
PRAI	US 2003-510466P	P	20031010		

L26 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:98819 CAPLUS

09/982,315

DN 142:198250
TI Medicaments for inhalation comprising an anticholinergic and a betamimetic
IN Meade, Christopher John Montague; Pairat, Michel; Pieper, Michael P.;
Konetzki, Ingo
PA Boehringer Ingelheim International G.m.b.H., Germany
SO U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005025718	A1	20050203	US 2004-891564	20040715
	CA 2534120	A1	20050217	CA 2004-2534120	20040717
	WO 2005013994	A1	20050217	WO 2004-EP8013	20040717
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1651224	A1	20060503	EP 2004-741123	20040717
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2007500676	T	20070118	JP 2006-521457	20040717
PRAI	EP 2003-17349	A	20030731		
	US 2003-508124P	P	20031002		
	WO 2004-EP8013	W	20040717		
OS	CASREACT 142:198250; MARPAT 142:198250				

L26 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:34613 CAPLUS
DN 142:120554
TI Bronchodilating β -agonist compositions
IN Banerjee, Partha S.; Akapo, Samuel O.; Chaudry, Imtiaz A.
PA USA
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005009923	A1	20050113	US 2004-887785	20040709
	WO 2005007142	A2	20050127	WO 2004-US22217	20040709
	WO 2005007142	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1660035	A2	20060531	EP 2004-777968	20040709
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-486386P	P	20030710		
	WO 2004-US22217	W	20040709		

L26 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:902155 CAPLUS
DN 141:384286
TI Novel encochleation methods, cochleates and methods of use
IN Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.;
Delmarre, David; Lu, Ruying
PA Biodelivery Sciences International, Inc., USA; University of Medicine and

09/982,315

Dentistry of New Jersey
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091578	A2	20041028	WO 2004-US11026	20040409
	WO 2004091578	A8	20050127		
	WO 2004091578	A3	20050331		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005013854	A1	20050120	US 2004-822230	20040409
	EP 1624858	A2	20060215	EP 2004-759375	20040409
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-461483P	P	20030409		
	US 2003-463076P	P	20030415		
	US 2003-499247P	P	20030828		
	US 2003-502557P	P	20030911		
	US 2003-532755P	P	20031224		
	US 2004-537252P	P	20040115		
	US 2004-556192P	P	20040324		
	WO 2004-US11026	W	20040409		

L26 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:780513 CAPLUS
DN 141:282812
TI Topical compositions containing ascorbic acid for treatment of infections that attack mucosa
IN Schneider, Daniel J.
PA USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080427	A2	20040923	WO 2004-US7803	20040312
	WO 2004080427	A3	20050506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2003-454133P	P	20030812		

L26 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:100805 CAPLUS
DN 140:151959
TI Inhalation compositions containing buffers and anti-inflammatory agents
IN Banerjee, Partha S.; Malladi, Ramana R.; Chaudry, Imtiaz A.
PA Dey, L.P., USA
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

McIntosh

09/982,315

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004023935	A1	20040205	US 2002-212573	20020802
PRAI	US 2002-212573		20020802		

L26 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:912854 CAPLUS
DN 139:386399
TI Catecholamine pharmaceutical compositions and methods
IN Root-Bernstein, Robert S.; Dillon, Patrick F.
PA USA
SO U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of Appl. No. PCT/US01/30272.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003216413	A1	20031120	US 2003-401421	20030328
WO	2002026223	A2	20020404	WO 2001-US30272	20010927
WO	2002026223	A3	20030508		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-236751P	P	20000929		
WO	2001-US30272	A2	20010927		

L26 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:875066 CAPLUS
DN 139:358772
TI Protease inhibitors and pulmonary surfactant associated proteins and their drug compositions for treatment and prevention of pulmonary inflammatory diseases
IN Cochrane, Charles G.; Oades, Zenaida G.; Revak, Susan D.; Niven, Ralph
PA The Scripps Research Institute, USA
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003090682	A2	20031106	WO 2003-US12731	20030425
WO	2003090682	A3	20040916		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2483102	A1	20031106	CA 2003-2483102	20030425
AU	2003223718	A1	20031110	AU 2003-223718	20030425
EP	1558273	A2	20050803	EP 2003-719918	20030425
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP	2005529885	T	20051006	JP 2003-587321	20030425
CN	1838964	A	20060927	CN 2003-814517	20030425
US	2005070477	A1	20050331	US 2004-971461	20041022
PRAI	US 2002-375968P	P	20020425		
WO	2003-US12731	W	20030425		

L26 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:855813 CAPLUS
DN 139:341715

McIntosh

09/982,315

TI Use of compositions containing petasin -containing, petasin-depleted or
petasin-free petasite extracts as specific COX-2 inhibitors
IN Rittinghausen, Reiner
PA Weber & Weber G.m.b.H. & Co. KG, Germany
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088985	A2	20031030	WO 2003-EP3756	20030411
	WO 2003088985	A3	20040226		
	WO 2003088985	A8	20040527		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10217939	A1	20031113	DE 2002-10217939	20020422
	AU 2003233964	A1	20031103	AU 2003-233964	20030411
	EP 1499334	A2	20050126	EP 2003-727288	20030411
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	DE 2002-10217939	A	20020422		
	WO 2003-EP3756	W	20030411		

L26 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:594728 CAPLUS

DN 137:145609

TI Antiasthmatic combinations with negligible side-effects containing
oxitropium salts and beta-2-agonists

IN Bozung, Karl-Heinz; Pairet, Michel; Reichl, Richard; Walland, Alexander

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060533	A2	20020808	WO 2002-EP704	20020124
	WO 2002060533	A3	20021212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10104370	A1	20020808	DE 2001-10104370	20010201
	US 2002179087	A1	20021205	US 2002-51516	20020117
	CA 2436510	A1	20020808	CA 2002-2436510	20020124
	AU 2002252981	A1	20020812	AU 2002-252981	20020124
	EP 1357976	A2	20031105	EP 2002-722033	20020124
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	DE 2001-10104370	A	20010201		
	US 2001-291843P	P	20010517		
	WO 2002-EP704	W	20020124		

L26 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:594727 CAPLUS

DN 137:145608

TI Antiasthmatic combinations with negligible side-effects containing
ipratropium salts and betamimetics

IN Bozung, Karl-Heinz; Pairet, Michel; Reichl, Richard; Walland, Alexander

PA Boehringer Ingelheim Pharma Kg, Germany

McIntosh

09/982,315

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060532	A1	20020808	WO 2002-EP674	20020124
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	DE 10104367	A1	20020808	DE 2001-10104367	20010201
	CA 2434872	A1	20020808	CA 2002-2434872	20020124
	EP 1357975	A1	20031105	EP 2002-712840	20020124
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
	JP 2004517942	T	20040617	JP 2002-560721	20020124
PRAI	DE 2001-10104367	A	20010201		
	WO 2002-EP674	W	20020124		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:256037 CAPLUS

DN 136:273216

TI Catecholamine adrenergic pharmaceutical compositions

IN Root-Bernstein, Robert S.; Dillon, Patrick F.

PA Board of Trustees Operating Michigan State University, USA

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026223	A2	20020404	WO 2001-US30272	20010927
	WO 2002026223	A3	20030508		
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	CA 2424021	A1	20020404	CA 2001-2424021	20010927
	EP 1326642	A2	20030716	EP 2001-975488	20010927
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
	JP 2004509920	T	20040402	JP 2002-530053	20010927
	US 2003216413	A1	20031120	US 2003-401421	20030328
PRAI	US 2000-236751P	P	20000929		
	WO 2001-US30272	W	20010927		

L26 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1985:400427 CAPLUS

DN 103:427

TI Desensitization of guinea pig airways to isoproterenol, and the effect of drugs

AU Wei, Erqing; Bian, Rulian

CS Dep. Antiasthmatic Drug Res., Zhejiang Med. Univ., Hangzhou, Peop. Rep. China

SO Yaoxue Xuebao (1984), 19(3), 161-6

CODEN: YHHPAL; ISSN: 0513-4870

DT Journal

LA Chinese

McIntosh

09/982,315

L26 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1977:83869 CAPLUS
DN 86:83869
TI Prevention of PGF2 α -induced bronchoconstriction by ascorbic acid in
asthmatic patients
AU Blanco, S.; Robuschi, M.; Grugni, A.; Allegra, L.
CS Clin. Tisiol. Mal. Appar. Respir., Milan, Italy
SO IRCS Medical Science: Library Compendium (1977), 5(1), 33
CODEN: IRLCDZ; ISSN: 0305-6651
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 17:39:56 ON 18 MAR 2007)

FILE 'REGISTRY' ENTERED AT 17:40:18 ON 18 MAR 2007

L1 STRUCTURE UPLOADED
L2 2160 S L1 FULL
E RESVERATROL/CN
L3 1 S E3
E ASCORBIC ACID/CN
L4 2 S E3
E DEHYDROASCORBIC ACID/CN
L5 2 S E3
E ASCORBATE/CN
L6 1 S E3
E ASCORBATE SALT/CN

FILE 'CAPLUS' ENTERED AT 17:42:48 ON 18 MAR 2007

L7 362 S L2 AND (L3 OR L4 OR L5 OR L6)
L8 9 S L7 AND PULMONARY
L9 2 S L7 AND AEROSOL
L10 4 S L7 AND (INTRANASAL OR INHALATION OR ENDOPULMONARY OR NEBULIZE
L11 0 S L7 AND NEBULIZER
L12 2 S L7 AND ASTHMA
S L1 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'REGISTRY' ENTERED AT 17:50:58 ON 18 MAR 2007

L13 4 S L1

FILE 'CAPLUS' ENTERED AT 17:50:58 ON 18 MAR 2007

L14 6 S L13
L15 6 S L14 AND (L2 OR L3 OR L4 OR L5 OR L6)

FILE 'CAPLUS' ENTERED AT 18:06:48 ON 18 MAR 2007

L16 0 S L7 AND PROPELLANT
L17 0 S L7 AND INHALER
L18 14 S L7 AND LUNG
L19 86667 S L3 OR L4 OR L5 OR L6
L20 362 S L2 AND L19
L21 155 S L19 AND ASTHMA
L22 221 S L19 AND AEROSOL
L23 2 S L7 AND AEROSOL
L24 12 S L2 AND AEROSOL
L25 21 S L2 AND ASTHMA
L26 23 S L21 AND L22

McIntosh